

Table S1. Potential outcomes to be predicted identified in a systematic review and review of other relevant literature.

| Outcomes | Models for pregnancy complications in women with GDM | | | | | Core outcome set for studies of GDM Treatment ¹ | Hyperglycaemia and Adverse Pregnancy Outcomes study ² | Model for insulin therapy initiation ³ |
|------------------------------------------------------|------------------------------------------------------|---------------------------------|--------------------------------------------|-------------------------------------|--------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------|
| | McIntyre <i>et al.</i> ⁴ | Park <i>et al.</i> ⁵ | Phaloprakarn and Tangjitgamol ⁶ | Pintaudi <i>et al.</i> ⁷ | Tomlinson <i>et al.</i> ⁸ | | | |
| Outcomes to be predicted | | | | | | | | |
| Birth of LGA neonate (> 90 th percentile) | x | x | | x | x | x | 1 ^o | x |
| HDP | | x (GH, PE) | x (PE) | | | x | 2 ^o (PE) | |
| Shoulder dystocia | x ^g | | | x | | | 2 ^o (shoulder dystocia or birth injury) | x |
| Nerve palsy | | | | | | | 2 ^o (shoulder dystocia or birth injury) | |
| Bone fracture | | | | | | | 2 ^o (shoulder dystocia or birth injury) | |
| Perinatal (fetal and neonatal) death | | | | x | | x (neonatal death, stillbirth) | | |
| Neonatal hypoglycaemia | x | x | | x | | x | 1 ^o (clinical) | x |
| Requirement for insulin therapy | | x | | | | x (Requirement & type of pharmacological therapy for hyperglycaemia) | | |

| Outcomes excluded from prediction | | | | | | | | |
|----------------------------------------|----------------|---|--|---|--|-------------------|-----------------------------------------|--------------------------------|
| Birth weight | | | | | | x | | |
| Preterm birth | | | | | | x | 2° (delivery before 27 weeks gestation) | x (Early delivery, < 37 weeks) |
| Adherence to the intervention | | | | | | x | | |
| GWG | | | | | | x | | |
| Caesarean delivery | x [#] | | | | | x (Mode of birth) | 1° (primary caesarean delivery) | x |
| SGA (<10 th percentile) | | | | x | | x | | x |
| GA at birth | | | | | | x | | |
| Neonatal jaundice | | x | | x | | | 2° (hyperbilirubinaemia) | x |
| Neonatal adiposity | x | | | | | | | |
| Neonatal hyperinsulinaemia | x | x | | | | | 1° | |
| Admission to the NICU | | x | | x | | | 2° | |
| Malformations | | | | x | | | | |
| Neonatal hypocalcaemia | | | | x | | | | |
| Neonatal respiratory distress syndrome | | | | x | | | | |
| Cord-blood serum C-peptide level | | | | | | | x | |

| | | | | | | | | |
|---------------------------|--|--|--|--|--|--|--|--|
| above the 90th percentile | | | | | | | | |
|---------------------------|--|--|--|--|--|--|--|--|

Abbreviations: GDM, gestational diabetes; COS, core outcome set; LGA, large-for-gestational age; HDP, hypertensive disorders of pregnancy; PE, preeclampsia, GH, gestational hypertension; 2°, primary outcome; 2°, secondary outcome; GWG, gestational weight gain; GA, gestational age; SGA, small-for-gestational age; OGTT, oral glucose tolerance test; NICU, neonatal intensive care unit.

REFERENCES

1. Egan AM, Bogdanet D, Griffin TP, et al. A core outcome set for studies of gestational diabetes mellitus prevention and treatment. *Diabetologia* 2020 doi: 10.1007/s00125-020-05123-6 [published Online First: 2020/03/21]

2. Hapo Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* 2008;358(19):1991-2002. doi: 10.1056/NEJMoa0707943 [published Online First: 2008/05/09]

3. Barnes RA, Wong T, Ross GP, et al. A novel validated model for the prediction of insulin therapy initiation and adverse perinatal outcomes in women with gestational diabetes mellitus. *Diabetologia* 2016;59(11):2331-38. doi: 10.1007/s00125-016-4047-8 [published Online First: 2016/07/10]

4. McIntyre HD, Gibbons KS, Lowe J, et al. Development of a risk engine relating maternal glycemia and body mass index to pregnancy outcomes. *Diabetes Res Clin Pract* 2018;139:331-38. doi: 10.1016/j.diabres.2018.02.036 [published Online First: 2018/03/20]

5. Park JS, Kim DW, Kwon JY, et al. Development of a Screening Tool for Predicting Adverse Outcomes of Gestational Diabetes Mellitus: A Retrospective Cohort Study. *Medicine (Baltimore)* 2016;95(1):e2204. doi: 10.1097/MD.0000000000002204 [published Online First: 2016/01/07]

6. Phaloprakarn C, Tangjitgamol S. Risk assessment for preeclampsia in women with gestational diabetes mellitus. *J Perinat Med* 2009;37(6):617-21. doi: 10.1515/JPM.2009.108 [published Online First: 2009/07/14]

7. Pintaudi B, Fresa R, Dalfra M, et al. The risk stratification of adverse neonatal outcomes in women with gestational diabetes (STRONG) study. *Acta Diabetol* 2018;55(12):1261-73. doi: 10.1007/s00592-018-1208-x [published Online First: 2018/09/18]

8. Tomlinson TM, Mostello DJ, Lim KH, et al. Fetal overgrowth in pregnancies complicated by diabetes: development of a clinical prediction index. *Arch Gynecol Obstet* 2018;298(1):67-74. doi: 10.1007/s00404-018-4758-9 [published Online First: 2018/04/28]